Today, new-generation cancer drugs have significantly improved both effectiveness and safety, especially targeted therapies.

Merck's cholesterol pill enlicitide ​decanoate and its cancer therapy sacituzumab tirumotecan, or sac-TMT, have been tapped ...

Vial, a clinical-stage biotech company, today announced growing enthusiasm among metabolic disease KOLs for Vial's INHBE siRNA, a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that ...

Dec 1 (Reuters) – Eli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S. patients, as demand for ...

What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...

Represents the first PD-1 inhibitor plus ADC regimens for this patient population These approvals are based on data from the Phase 3 KEYNOTE-905 trial (also known as EV-303), which was conducted in ...

Keytruda and Padcev combination shows improved event-free and overall survival in muscle invasive bladder cancer patients ineligible for cisplatin. The KEYNOTE-905/EV-303 trial demonstrated ...

Keytruda Qlex (pembrolizumab and berahydaluronidas alfa-pmph) is a prescription drug approved to treat different types of cancer, such as non-small cell lung cancer and head and neck cancer. Keytruda ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Merck, which has claimed ...

(Reuters) -Merck and Eisai's experimental combination treatment helped extend the time certain patients with advanced kidney cell cancer lived without their disease progressing, according to interim ...